Envafolimab
- Generic Name
- Envafolimab
- Drug Type
- Biotech
- CAS Number
- 2102192-68-5
- Unique Ingredient Identifier
- ES1M06M6QH
- Indication
用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer
Phase 2
- Conditions
- Colorectal Neoplasms
- Interventions
- Drug: recombinant human endostatin (endostatin)
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-09-22
- Target Recruit Count
- 30
- Registration Number
- NCT05551247
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Anhui Chest Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05529355
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Phase 1
Active, not recruiting
- Conditions
- Soft Tissue SarcomaMetastatic SarcomaAdvanced Sarcoma
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05448820
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Phase 2
- Conditions
- Ovarian Cancer, Epithelial
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05422183
- Locations
- 🇨🇳
Zhongda Hospital, Nanjing, Jiangsu, China
RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05417230
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Anhui Provincial Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05414630
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
Phase 2
Recruiting
- Conditions
- EnvafolimabPD-L1Induction ChemotherapyLocally Advanced Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT05397769
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric
Phase 2
Not yet recruiting
- Conditions
- Gastric/Gastroesophageal Junction AdenocarcinomaRadiotherapyImmunotherapy
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 35
- Registration Number
- NCT05387681
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Second Xiangya Hospital of Central South University
- Target Recruit Count
- 42
- Registration Number
- NCT05360979
- Locations
- 🇨🇳
the second Xiangya hospital, Changsha, Hunan, China
To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT05335460
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath